Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Hepatocellular Carcinoma Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Brachytherapy
      • 1.3.3 Chemotherapy
      • 1.3.4 Local Ablation Therapy
    • 1.4 Market Segment by Application
      • 1.4.1 Global Hepatocellular Carcinoma Drugs Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Clinics
      • 1.4.4 Cancer Rehabilitation Centers
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Hepatocellular Carcinoma Drugs Market Size
      • 2.1.1 Global Hepatocellular Carcinoma Drugs Revenue 2014-2025
      • 2.1.2 Global Hepatocellular Carcinoma Drugs Sales 2014-2025
    • 2.2 Hepatocellular Carcinoma Drugs Growth Rate by Regions
      • 2.2.1 Global Hepatocellular Carcinoma Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Hepatocellular Carcinoma Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Hepatocellular Carcinoma Drugs Sales by Manufacturers
      • 3.1.1 Hepatocellular Carcinoma Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Hepatocellular Carcinoma Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Hepatocellular Carcinoma Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Hepatocellular Carcinoma Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Hepatocellular Carcinoma Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Hepatocellular Carcinoma Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Hepatocellular Carcinoma Drugs Market
    • 3.6 Key Manufacturers Hepatocellular Carcinoma Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Brachytherapy Sales and Revenue (2014-2019)
      • 4.1.2 Chemotherapy Sales and Revenue (2014-2019)
      • 4.1.3 Local Ablation Therapy Sales and Revenue (2014-2019)
    • 4.2 Global Hepatocellular Carcinoma Drugs Sales Market Share by Type
    • 4.3 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type
    • 4.4 Hepatocellular Carcinoma Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Hepatocellular Carcinoma Drugs Sales by Application

    6 United States

    • 6.1 United States Hepatocellular Carcinoma Drugs Breakdown Data by Company
    • 6.2 United States Hepatocellular Carcinoma Drugs Breakdown Data by Type
    • 6.3 United States Hepatocellular Carcinoma Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Hepatocellular Carcinoma Drugs Breakdown Data by Company
    • 7.2 European Union Hepatocellular Carcinoma Drugs Breakdown Data by Type
    • 7.3 European Union Hepatocellular Carcinoma Drugs Breakdown Data by Application

    8 China

    • 8.1 China Hepatocellular Carcinoma Drugs Breakdown Data by Company
    • 8.2 China Hepatocellular Carcinoma Drugs Breakdown Data by Type
    • 8.3 China Hepatocellular Carcinoma Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Company
    • 9.2 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Type
    • 9.3 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Application
    • 9.4 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Hepatocellular Carcinoma Drugs Sales by Countries
      • 9.4.2 Rest of World Hepatocellular Carcinoma Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Bayer
      • 10.1.1 Bayer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.1.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.1.5 Bayer Recent Development
    • 10.2 Eli Lilly
      • 10.2.1 Eli Lilly Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.2.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.2.5 Eli Lilly Recent Development
    • 10.3 Johnson and Johnson
      • 10.3.1 Johnson and Johnson Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.3.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.3.5 Johnson and Johnson Recent Development
    • 10.4 Pfizer
      • 10.4.1 Pfizer Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.4.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.4.5 Pfizer Recent Development
    • 10.5 Bristol-Myers Squibb
      • 10.5.1 Bristol-Myers Squibb Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.5.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.5.5 Bristol-Myers Squibb Recent Development
    • 10.6 Celgene
      • 10.6.1 Celgene Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.6.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.6.5 Celgene Recent Development
    • 10.7 F. Hoffmann-la Roche
      • 10.7.1 F. Hoffmann-la Roche Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.7.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.7.5 F. Hoffmann-la Roche Recent Development
    • 10.8 Gilead
      • 10.8.1 Gilead Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.8.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.8.5 Gilead Recent Development
    • 10.9 GlaxoSmithKline
      • 10.9.1 GlaxoSmithKline Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.9.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.9.5 GlaxoSmithKline Recent Development
    • 10.10 Merck
      • 10.10.1 Merck Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
      • 10.10.4 Hepatocellular Carcinoma Drugs Product Introduction
      • 10.10.5 Merck Recent Development
    • 10.11 Novartis

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Hepatocellular Carcinoma Drugs Sales Channels
      • 11.2.2 Hepatocellular Carcinoma Drugs Distributors
    • 11.3 Hepatocellular Carcinoma Drugs Customers

    12 Market Forecast

    • 12.1 Global Hepatocellular Carcinoma Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Hepatocellular Carcinoma Drugs Sales Forecast by Type
    • 12.3 Global Hepatocellular Carcinoma Drugs Sales Forecast by Application
    • 12.4 Hepatocellular Carcinoma Drugs Forecast by Regions
      • 12.4.1 Global Hepatocellular Carcinoma Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Hepatocellular Carcinoma Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
      The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.
      In 2019, the market size of Hepatocellular Carcinoma Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hepatocellular Carcinoma Drugs.

      This report studies the global market size of Hepatocellular Carcinoma Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Hepatocellular Carcinoma Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Bayer
      Eli Lilly
      Johnson and Johnson
      Pfizer
      Bristol-Myers Squibb
      Celgene
      F. Hoffmann-la Roche
      Gilead
      GlaxoSmithKline
      Merck
      Novartis

      Market Segment by Product Type
      Brachytherapy
      Chemotherapy
      Local Ablation Therapy

      Market Segment by Application
      Hospitals
      Clinics
      Cancer Rehabilitation Centers

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Hepatocellular Carcinoma Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Hepatocellular Carcinoma Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Hepatocellular Carcinoma Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now